8-K - Summit Therapeutics Inc. | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On October 21, 2025, Summit Therapeutics Inc. (the “Company”) entered into securities purchase agreements (the “Purc

Material Agreement

$18.74$500.0M

Source Document

3.02

. Item 7.01 Regulation FD Disclosure. On October 21, 2025, the Company issued a press release announcing the Private Placement, a copy of which is attached as E

Securities Issuance

7.01

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of th

Regulation Fd

9.01

Financial Statement and Exhibits. (d) Exhibits Exhibit No. Description 10.1 † Form of Securities Purchase Agreement 10.2 † Form of Registration Rights Agreement

Exhibits Only

Source Document

Exhibits (4)

10.1

EX-10.1

10.2

EX-10.2

8-K

99.1

EX-99.1